CIK 0002044725 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Evommune, Inc.
Sign in to watch- Ticker
- EVMN
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 850742575
- Phone
- (650) 223-7745
- Business address
- 1891 PAGE MILL RD, PALO ALTO, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-09 | Moss Gregory S. Chief Business & Legal Officer | Shares withheld for taxes | −13,624 | $17.84 | $243K | 60,835 |
| 2025-12-09 | Bauer Eugene Chief Medical Officer | Shares withheld for taxes | −1,478 | $17.84 | $26K | 270,818 |
| 2025-12-09 | Pena Luis C. President & CEO | Shares withheld for taxes | −28,138 | $17.84 | $502K | 654,683 |
| 2025-12-08 | Bauer Eugene Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-11-07 | Verduyn-van Weegen Felice Isabel Director | Conversion | +3,367,133 | 3,367,133 | ||
| 2025-11-07 | Verduyn-van Weegen Felice Isabel Director | Purchase | +1,562,500 | $16.00 | $25.0M | 4,929,633 |
| 2025-11-07 | Verduyn-van Weegen Felice Isabel Director | Conversion · Series A Preferred Stock | −15,493,466 | 0 | ||
| 2025-11-07 | Verduyn-van Weegen Felice Isabel Director | Conversion · Series B Preferred Stock | −5,090,000 | 0 | ||
| 2025-11-07 | Verduyn-van Weegen Felice Isabel Director | Conversion · Series C Preferred Stock | −6,585,011 | 0 | ||
| 2025-11-07 | Patel Jeegar Pravinkumar Chief Scientific Officer | Conversion | +3,175 | 57,091 | ||
| 2025-11-07 | Patel Jeegar Pravinkumar Chief Scientific Officer | Conversion · Series B Preferred Stock | −25,000 | 0 | ||
| 2025-11-07 | Drew Janice Suzann EVP, Operations | Conversion | +1,587 | 72,868 | ||
| 2025-11-07 | Drew Janice Suzann EVP, Operations | Conversion · Series B Preferred Stock | −12,500 | 0 | ||
| 2025-11-07 | LSP 7 Cooperative UA 10% owner | Conversion | +3,367,133 | 3,367,133 | ||
| 2025-11-07 | LSP 7 Cooperative UA 10% owner | Purchase | +1,562,500 | $16.00 | $25.0M | 4,929,633 |
| 2025-11-07 | LSP 7 Cooperative UA 10% owner | Conversion · Series A Preferred Stock | −15,493,466 | 0 | ||
| 2025-11-07 | LSP 7 Cooperative UA 10% owner | Conversion · Series B Preferred Stock | −5,090,000 | 0 | ||
| 2025-11-07 | LSP 7 Cooperative UA 10% owner | Conversion · Series C Preferred Stock | −6,585,011 | 0 | ||
| 2025-11-07 | Carver Kyle Chief Financial Officer | Conversion | +3,175 | 75,800 | ||
| 2025-11-07 | Carver Kyle Chief Financial Officer | Conversion · Series B Preferred Stock | −25,000 | 0 |
Page 3 of 6 · 109 trades